Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of General Psychiatry
Published in: Annals of General Psychiatry 1/2020

01-12-2020 | Obsessive-Compulsive Disorder | Review

Efficacy of nicotine administration on obsessions and compulsions in OCD: a systematic review

Authors: Daria Piacentino, Annalisa Maraone, Valentina Roselli, Isabella Berardelli, Massimo Biondi, Georgios D. Kotzalidis, Massimo Pasquini

Published in: Annals of General Psychiatry | Issue 1/2020

Login to get access

Abstract

Background

Preliminary studies have tested nicotine as a novel treatment for OCD patients who respond partially/incompletely or not at all to first and second-line treatment strategies, with the former represented by SSRIs or clomipramine, and the latter by switching to another SSRI, or augmentation with atypical antipsychotics, and/or combination with/switching to cognitive–behavioural therapy. Some studies found nicotine-induced reduction of obsessive thoughts and/or compulsive behaviour in OCD patients. We aimed to evaluate the efficacy of nicotine administration in OCD patients.

Methods

We searched the PubMed, ScienceDirect Scopus, CINHAL, Cochrane, PsycINFO/PsycARTICLES, and EMBASE databases from inception to the present for relevant papers. The ‘Preferred Reporting Items for Systematic Review and Meta-Analyses’ (PRISMA) standards were used. We included all studies focusing on the effects of nicotine administration on OCD patients’ obsessions or compulsions. Studies could be open-label, cross-sectional, randomized controlled trials, case series or case reports.

Results

A total of five studies could be included. Nicotine administration may ameliorate behavioural features and recurrent thoughts of severe, treatment-resistant OCD patients; however, in one study it was not associated with OC symptom improvement or cognitive enhancement across various executive function subdomains.

Conclusions

Although encouraging, the initial positive response from the use of nicotine in OCD needs testing in large controlled studies. This, however, raises ethical issues related to nicotine administration, due to its addiction potential, which were not addressed in the limited literature we examined. As an alternative, novel treatments with drugs able to mimic only the positive effects of nicotine could be implemented.
Literature
1.
Abramovitch A, Abramowitz JS, Mittelman A. The neuropsychology of adult obsessive-compulsive disorder: a meta-analysis. Clin Psychol Rev. 2013;33:1163–71.PubMedCrossRef
2.
Abramovitch A, Pizzagalli DA, Geller DA, Reuman L, Wilhelm S. Cigarette smoking in obsessive-compulsive disorder and unaffected parents of OCD patients. Eur Psychiatry. 2015;30(1):137–44.PubMedCrossRef
3.
Abramowitz JS, McKay D, Storch EA, editors. The Wiley Handbook of Obsessive Compulsive Disorders. Malden: John Wiley & Sons; 2017.
4.
Aizenberg D, Hermesh H, Karp L, Munitz H. Pseudocholinesterase in obsessive-compulsive patients. Psychiatry Res. 1989;27(1):65–9.PubMedCrossRef
5.
Albert U, Marazziti D, Di Salvo G, Solia F, Rosso G, Maina G. A systematic review of evidence-based treatment strategies for obsessive-compulsive disorder resistant to first-line pharmacotherapy. Curr Med Chem. 2018;25:5647–61.PubMedCrossRef
6.
Albert U, Di Salvo G, Solia F, Rosso G, Maina G. Combining drug and psychological treatments for obsessive-compulsive disorder: what is the evidence, when and for whom. Curr Med Chem. 2018;25:5632–46.PubMedCrossRef
7.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition-Revised (DSM-III). Washington, DC: APA; 1980.
8.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition-Revised (DSM-III-R®). Washington, DC: APA; 1987.
9.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV®). Washington, DC: APA; 1994.
10.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text Revision (DSM-IV-TRTM). Washington, DC: APA; 2000.CrossRef
11.
12.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5TM). Arlington, VA: APA; 2013.CrossRef
13.
Aouizerate B, Guehl D, Cuny E, Rougier A, Burbaud P, Tignol J, et al. Updated overview of the putative role of the serotoninergic system in obsessive-compulsive disorder. Neuropsychiatr Dis Treat. 2005;1(3):231–43.PubMedPubMedCentral
14.
Araki H, Suemaru K, Gomita Y. Neuronal nicotinic receptor and psychiatric disorders: functional and behavioral effects of nicotine. Jpn J Pharmacol. 2002;88(2):133–8.PubMedCrossRef
15.
Austin LS, Lydiard RB, Ballenger JC, Cohen BM, Laraia MT, Zealberg JJ, et al. Dopamine blocking activity of clomipramine in patients with obsessive-compulsive disorder. Biol Psychiatry. 1991;30(3):225–32.PubMedCrossRef
16.
Awtry TL, Werling LL. Acute and chronic effects of nicotine on serotonin uptake in prefrontal cortex and hippocampus of rats. Synapse. 2003;50(3):206–11.PubMedCrossRef
17.
Aznar S, Kostova V, Christiansen SH, Knudsen GM. Alpha 7 nicotinic receptor subunit is present on serotonin neurons projecting to hippocampus and septum. Synapse. 2005;55(3):196–200.PubMedCrossRef
18.
Bandelow B, Sher L, Bunevicius R, Hollander E, Kasper S, Zohar J, Möller H-J. WFSBP Task Force on Mental Disorders in Primary Care; WFSBP Task Force on Anxiety Disorders, OCD and PTSD. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract. 2012;16(2):77–84. Errata: Int J Psychiatry Clin Pract. 2012;16(3):242; Int J Psychiatry Clin Pract. 2013;17(1):76.
19.
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–71.PubMedCrossRef
20.
Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56(6):893–7.PubMedCrossRef
21.
Bejerot S, Humble M. Low prevalence of smoking among patients with obsessive-compulsive disorder. Compr Psychiatry. 1999;40:268–72.PubMedCrossRef
22.
Bejerot S, von Knorring L, Ekselius L. Personality traits and smoking in patients with obsessive-compulsive disorder. Eur Psychiatry. 2000;15:395–401.PubMedCrossRef
23.
Bergman J, Miodownik C, Lerner PP, Miodownik E, Shulkin A, Lerner V. Donepezil as Add-on treatment for resistant obsessive-compulsive disorder: retrospective case series. Clin Neuropharmacol. 2016;39(4):194–6.PubMedCrossRef
24.
Beucke JC, Sepulcre J, Talukdar T, Linnman C, Zschenderlein K, Endrass T, et al. Abnormally high degree connectivity of the orbitofrontal cortex in obsessive-compulsive disorder. JAMA Psychiatry. 2013;70(6):619–29.PubMedCrossRef
25.
Bhattacharyya S, Chakraborty K. Glutamatergic dysfunction—newer targets for anti-obsessional drugs. Recent Pat CNS Drug Discov. 2007;2(1):47–55.PubMedCrossRef
26.
Brody AL, Mandelkern MA, London ED, Childress AR, Lee GS, Bota RG, et al. Brain metabolic changes during cigarette craving. Arch Gen Psychiatry. 2002;59(12):1162–72.PubMedCrossRef
27.
Caldirola D, Daccò S, Grassi M, Citterio A, Menotti R, Cavedini P, et al. Effects of cigarette smoking on neuropsychological performance in mood disorders: a comparison between smoking and nonsmoking inpatients. J Clin Psychiatry. 2013;74(2):e130–136.PubMedCrossRef
28.
Caldirola D, Cavedini P, Riva A, Di Chiaro NV, Perna G. Cigarette smoking has no pro-cognitive effect in subjects with obsessive-compulsive disorder. A preliminary study. Psychiatr Danub. 2016;28(1):86–90.PubMed
29.
Carlsson ML. On the role of cortical glutamate in obsessive-compulsive disorder and attention-deficit hyperactivity disorder, two phenomenologically antithetical conditions. Acta Psychiatr Scand. 2000;102(6):401–13.PubMedCrossRef
30.
Carlsson ML and Carlsson A. Use of a nicotine receptor agonist in the treatment of obsessive compulsive behavior. Europe (EPC), Patent No. 126 846, New Zealand Patent No. 511 226, 2000.
31.
Castle D, Bosanac P, Rossell S. Treating OCD: what to do when first-line therapies fail. Australas Psychiatry. 2015;23(4):350–3.PubMedCrossRef
32.
Coluccia A, Fagiolini A, Ferretti F, Pozza A, Costoloni G, Bolognesi S, et al. Adult obsessive-compulsive disorder and quality of life outcomes: a systematic review and meta-analysis. Asian J Psychiatr. 2016;22:41–52.PubMedCrossRef
33.
Danish University Antidepressant Group (DUAG). Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology. 1989;90:131–8.
34.
Danish University Antidepressant Group (DUAG). Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Dis. 1990;18:289–99.CrossRef
35.
Del Casale A, Sorice S, Padovano A, Simmaco M, Ferracuti S, Lamis DA, Rapinesi C, Sani G, Girardi P, Kotzalidis GD, Pompili M. Psychopharmacological treatment of obsessive-compulsive disorder (OCD). Curr Neuropharmacol. 2019;17(8):710–36.PubMedPubMedCentralCrossRef
36.
Dell’Osso B, Nicolini H, Lanzagorta N, Benatti B, Spagnolin G, Palazzo MC, et al. Cigarette smoking in patients with obsessive compulsive disorder: a report from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS). CNS Spectr. 2015;20(5):469–73.PubMedCrossRef
37.
Denys D, Zohar J, Westenberg HG. The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. J Clin Psychiatry. 2004;14:11–7.
38.
Exley R, Clements MA, Hartung H, McIntosh JM, Franklin M, Bermudez I, Cragg SJ. Striatal dopamine transmission is reduced after chronic nicotine with a decrease in α6-nicotinic receptor control in nucleus accumbens. Eur J Neurosci. 2013;38:3036–43.PubMed
39.
Ferreira GM, Yücel M, Dawson A, Lorenzetti V, Fontenelle LF. Investigating the role of anticipatory reward and habit strength in obsessive-compulsive disorder. CNS Spectr. 2017;9:1–10.
40.
Freud S. Erinnern, Wiederholen und Durcharbeiten. Weitere Ratschläge zur Technik der Psychoanalyse. GW X, 1. Auflage 1946; 8. Auflage 1991, pp. 126–136, S. Fischer Verlag, Frankfurt am Main; 1914.
41.
Fujii S, Ji Z, Morita N, Sumikawa K. Acute and chronic nicotine exposure differentially facilitate the induction of LTP. Brain Res. 1999;846(1):137–43.PubMedCrossRef
42.
Gillan CM, Sahakian BJ. Which is the driver, the obsessions or the compulsions, in OCD? Neuropsychopharmacology. 2015;40(1):247–8.PubMedCrossRef
43.
Gillan CM, Apergis-Schoute AM, Morein-Zamir S, Urcelay GP, Sule A, Fineberg NA. Functional neuroimaging of avoidance habits in obsessive-compulsive disorder. Am J Psychiatry. 2015;172(3):284–93.PubMedCrossRef
44.
Girod R, Barazangi N, McGehee D, Role LW. Facilitation of glutamatergic neurotransmission by presynaptic nicotinic acetylcholine receptors. Neuropharmacology. 2000;39(13):2715–25.PubMedCrossRef
45.
Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL. The Yale-Brown Obsessive Compulsive Scale: I. Development, use, and reliability. Arch Gen Psychiatry. 1989;46:1006–111.PubMedCrossRef
46.
Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, et al. The Yale-Brown Obsessive Compulsive Scale: II. Validity. Arch Gen Psychiatry. 1989;46:1012–6.PubMedCrossRef
47.
Goodman WK, McDougle CJ, Price LH. The role of serotonin and dopamine in the pathophysiology of obsessive compulsive disorder. Int Clin Psychopharmacol. 1992;7(Suppl 1):35–8.PubMedCrossRef
48.
Guy W. Clinical global impressions. In: Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration, Rockville, MD. 1976, pp. 217–222.
49.
Harsányi A, Csigó K, Demeter G, Németh A. A kenyszerbetegseg uj megkozelitese: a dopaminerg teoriak [New approach to obsessive-compulsive disorder: dopaminergic theories–in Hungarian]. Psychiatr Hung. 2007;22(4):248–58.PubMed
50.
Hartmann A. Clinical pharmacology of nondopaminergic drugs in Tourette syndrome. Int Rev Neurobiol. 2013;112:351–72.PubMedCrossRef
51.
Hedman E, Ljótsson B, Axelsson E, Andersson G, Rück C, Andersson E. Health anxiety in obsessive compulsive disorder and obsessive compulsive symptoms in severe health anxiety: an investigation of symptom profiles. J Anxiety Disord. 2017;45:80–6.PubMedCrossRef
52.
Howson AL, Batth S, Ilivitsky V, Boisjoli A, Jaworski M, Mahoney C, et al. Clinical and attentional effects of acute nicotine treatment in Tourette's syndrome. Eur Psychiatry. 2004;19(2):102–12.PubMedCrossRef
53.
Insel TR, Donnelly EF, Lalakea ML, Alterman IS, Murphy DL. Neurological and neuropsychological studies of patients with obsessive-compulsive disorder. Biol Psychiatry. 1983;18(7):741–51.PubMed
54.
Issari Y, Jakubovski E, Bartley CA, Pittenger C, Bloch MH. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis. J Clin Psychiatry. 2016;77(5):e605–611.PubMedCrossRef
55.
56.
Kenny PJ, File SE, Neal MJ. Evidence for a complex influence of nicotinic acetylcholine receptors on hippocampal serotonin release. J Neurochem. 2000;75(6):2409–14.PubMedCrossRef
57.
Koo MS, Kim EJ, Roh D, Kim CH. Role of dopamine in the pathophysiology and treatment of obsessive-compulsive disorder. Expert Rev Neurother. 2010;10(2):275–90.PubMedCrossRef
58.
Lucey JV, Butcher G, Clare AW, Dinan TG. Elevated growth hormone responses to pyridostigmine in obsessive-compulsive disorder: evidence of cholinergic supersensitivity. Am J Psychiatry. 1993;150(6):961–2.PubMedCrossRef
59.
Lundberg S, Carlsson A, Norfeldt P, Carlsson ML. Nicotine treatment of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:1195–9.PubMedCrossRef
60.
Mansvelder HD, McGehee DS. Long-term potentiation of excitatory inputs to brain reward areas by nicotine. Neuron. 2000;27(2):349–57.PubMedCrossRef
61.
Mansvelder HD, Keath JR, McGehee DS. Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron. 2002;33(6):905–19.PubMedCrossRef
62.
Marazziti D, Golia F, Consoli G, Presta S, Pfanner C, Carlini M, Mungai F, Catena DM. Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients. CNS Spectr. 2008;13(11):971–6.PubMedCrossRef
63.
Marazziti D, Albert U, Mucci F, Piccinni A. The glutamate and the immune systems: new targets for the pharmacological treatment of OCD. Curr Med Chem. 2018;25:5731–8.PubMedCrossRef
64.
Maskos U. Emerging concepts: novel integration of in vivo approaches to localize the function of nicotinic receptors. J Neurochem. 2007;100(3):596–602.PubMedCrossRef
65.
Metaxas A, Keyworth HL, Yoo JH, Chen Y, Kitchen I, Bailey A. The stereotypy-inducing and OCD-like effects of chronic ‘binge’ cocaine are modulated by distinct subtypes of nicotinic acetylcholine receptors. Br J Pharmacol. 2012;167:450–64.PubMedPubMedCentralCrossRef
66.
Milad MR, Rauch SL. Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways. Trends Cogn Sci. 2012;16(1):43–51.PubMedCrossRef
67.
Milberger S, Biederman J, Faraone SV, Chen L, Jones J. Further evidence of an association between attention-deficit/hyperactivity disorder and cigarette smoking. Findings from a high-risk sample of siblings. Am J Addict. 1997;6:205–17.PubMed
68.
Mitra S, Mucha M, Khatri SN, Glenon R, Schulte MK, Bult-Ito A. Attenuation of compulsive-like behavior through positive allosteric modulation of α4β2 nicotinic acetylcholine receptors in non-induced compulsive-like mice. Front Behav Neurosci. 2017;10:244.PubMedPubMedCentralCrossRef
69.
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses, the PRISMA statement. BMJ. 2009;339:332–6.CrossRef
70.
Morisano D, Wing VC, Sacco KA, Arenovich T, George TP. Effects of tobacco smoking on neuropsychological function in schizophrenia in comparison to other psychiatric disorders and non-psychiatric controls. Am J Addict. 2013;22:46–53.PubMedCrossRef
71.
Nashmi R, Lester HA. CNS localization on neuronal nicotinic receptors. J Mol Neurosci. 2006;30:181–4.PubMedCrossRef
72.
National Institute for Health and Clinical Excellence (NICE). Obsessive-compulsive disorder and body dysmorphic disorder: treatment Clinical guideline [CG31]. London: NICE; 2005.
73.
Okasha A, Rafaat M, Mahallawy N, El Nahas G, El Dawla AS, Sayed M, et al. Cognitive dysfunction in obsessive-compulsive disorder. Acta Psychiatr Scand. 2000;101(4):281–5.PubMedCrossRef
74.
Olver JS, O'Keefe G, Jones GR, Burrows GD, Tochon-Danguy HJ, Ackermann U, Scott A, Norman TR. Dopamine D1 receptor binding in the striatum of patients with obsessive-compulsive disorder. J Affect Disord. 2009;114:321–6.PubMedCrossRef
75.
Pasquini M, Garavini A, Biondi M. Nicotine augmentation for refractory obsessive-compulsive disorder. A case report. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:157–9.PubMedCrossRef
76.
Phillips KA, Stein DJ, editors. Handbook on obsessive-compulsive and related disorders. Arlington, VA: American Psychiatric Publishing; 2015.
77.
Piacentino D, Pasquini M, Cappelletti S, Chetoni C, Sani G, Kotzalidis GD. Pharmacotherapy for hoarding disorder: how did the picture change since its excision from OCD? Curr Neuropharmacol. 2019;17(8):808–15.PubMedPubMedCentralCrossRef
78.
Picciotto MR, Caldarone BJ, King SL, Zachariou V. Nicotinic receptors in the brain. Links between molecular biology and behavior. Neuropsychopharmacology. 2000;22(5):451–65.PubMedCrossRef
79.
Piggott TA, Seay SM. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry. 1999;60:101–6.CrossRef
80.
Robbins TW, James M, Owen AM, Sahakian BJ, Lawrence AD, McInnes L. A study of performance on tests from the CANTAB battery sensitive to frontal lobe dysfunction in a large sample of normal volunteers: implications for theories of executive functioning and cognitive aging Cambridge Neuropsychological Test Automated Battery. J Int Neuropsychol Soc. 1998;4(5):474–90.PubMedCrossRef
81.
Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry. 2010;15:53–63.PubMedCrossRef
82.
Salín-Pascual RJ, Basañez-Villa E. Changes in compulsion and anxiety symptoms with nicotine transdermal patches in non-smoking obsessive-compulsive disorder patients. Rev Invest Clin. 2003;55:650–4.PubMed
83.
Sanberg PR, Vindrola-Padros C, Shytle RD. Translating laboratory discovery to the clinic: from nicotine and mecamylamine to Tourette’s, depression, and beyond. Physiol Behav. 2012;107(5):801–8.PubMedPubMedCentralCrossRef
84.
Sher KJ, Mann B, Frost RO. Cognitive dysfunction in compulsive checkers: further explorations. Behav Res Ther. 1984;22(5):493–502.PubMedCrossRef
85.
Shin DJ, Jung WH, He Y, Wang J, Shim G, Byun MS. The effects of pharmacological treatment on functional brain connectome in obsessive-compulsive disorder. Biol Psychiatry. 2014;75(8):606–14.PubMedCrossRef
86.
Silver AA, Shytle RD, Philipp MK, Wilkinson BJ, McConville B, Sanberg PR. Transdermal nicotine and haloperidol in Tourette’s disorder: a double-blind placebo-controlled study. J Clin Psychiatry. 2001;62(9):707–14.PubMedCrossRef
87.
Smith EA, Russell A, Lorch E, Banerjee SP, Rose M, Ivey J, et al. Increased medial thalamic choline found in pediatric patients with obsessive-compulsive disorder versus major depression or healthy control subjects: a magnetic resonance spectroscopy study. Biol Psychiatry. 2003;54(12):1399–405.PubMedCrossRef
88.
Snyder HR, Kaiser RH, Warren SL, Heller W. Obsessive-compulsive disorder is associated with broad impairments in executive function: a meta-analysis. Clin Psychol Sci. 2015;3(2):301–30.PubMedCrossRef
89.
Spitzer RL, Gibbon M, Williams J, Endicott J. Global Assessment of Functioning (GAF) Scale. In: Sederer LI, Dickey B, editors. Outcomes assessment in clinical practice. Baltimore, MD: Williams & Wilkins; 1996. p. 76–78.
90.
Stein DJ, Hollander E, Cohen L. Neuropsychiatry of obsessive-compulsive disorder. In: Hollander E, Zohar J, Marazziti D, Olivier B, editors. Current Insights in Obsessive-Compulsive Disorder. Chichester, West Sussex: Wiley; 1994. p. 167–182.
91.
Storch EA, Lewin AB, editors. Clinical handbook of obsessive-compulsive and related disorders. A case-based approach to treating pediatric and adult populations. Berlin: Springer; 2016.
92.
Szechtman H, Sulis W, Eilam D. Quinpirole induces compulsive checking behavior in rats: a potential animal model of obsessive-compulsive disorder (OCD). Behav Neurosci. 1998;112:1475–85.PubMedCrossRef
93.
Szechtman H, Culver K, Eilam D. Role of dopamine systems in obsessive-compulsive disorder (OCD): implications from a novel psychostimulant-induced animal model. Pol J Pharmacol. 1999;51:55–61.PubMed
94.
Szechtman H, Eckert MJ, Tse WS, Boersma JT, Bonura CA, McClelland JZ, et al. Compulsive checking behavior of quinpirole-sensitized rats as an animal model of Obsessive-Compulsive Disorder (OCD): form and control. BMC Neurosci. 2001;2:4.PubMedPubMedCentralCrossRef
95.
Tallis F, Pratt P, Jamani N. Obsessive compulsive disorder, checking, and non-verbal memory: a neuropsychological investigation. Behav Res Ther. 1999;37(2):161–6.PubMedCrossRef
96.
Tan O, Taş C. Symptom dimensions, smoking and impulsiveness in obsessive-compulsive disorder. Psychiatr Danub. 2015;27(4):397–405.PubMed
97.
Termine C, Selvini C, Rossi G, Balottin U. Emerging treatment strategies in Tourette syndrome: what's in the pipeline? Int Rev Neurobiol. 2013;112:445–80.PubMedCrossRef
98.
The Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry. 1991;48(8):730–8.CrossRef
99.
Tizabi Y, Louis VA, Taylor CT, Waxman D, Culver KE, Szechtman H. Effect of nicotine on quinpirole-induced checking behavior in rats: implications for obsessive-compulsive disorder. Biol Psychiatry. 2002;51(2):164–71.PubMedCrossRef
100.
Tolin DF, Abramowitz JS, Brigidi BD, Amir N, Street GP, Foa EB. Memory and memory confidence in obsessive-compulsive disorder. Behav Res Ther. 2001;39(8):913–27.PubMedCrossRef
101.
102.
Wallace TL, Bertrand D. Importance of the nicotinic acetylcholine receptor system in the prefrontal cortex. Biochem Pharmacol. 2013;85:1713–20.PubMedCrossRef
103.
Wing VC, Bacher I, Sacco KA, George TP. Neuropsychological performance in patients with schizophrenia and controls as a function of cigarette smoking status. Psychiatry Res. 2011;188:320–6.PubMedPubMedCentralCrossRef
104.
Zabala A, Eguiluz JI, Segarra R, Enjuto S, Ezcurra J, González Pinto A. Cognitive performance and cigarette smoking in first-episode psychosis. Eur Arch Psychiatry Clin Neurosci. 2009;259(2):65–71.PubMedCrossRef
105.
Zitterl W, Urban C, Linzmayer L, Aigner M, Demal U, Semler B. Memory deficits in patients with DSM-IV obsessive-compulsive disorder. Psychopathology. 2001;34(3):113–7.PubMedCrossRef
Metadata
Title
Efficacy of nicotine administration on obsessions and compulsions in OCD: a systematic review
Authors
Daria Piacentino
Annalisa Maraone
Valentina Roselli
Isabella Berardelli
Massimo Biondi
Georgios D. Kotzalidis
Massimo Pasquini
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Annals of General Psychiatry / Issue 1/2020
Electronic ISSN: 1744-859X
DOI
https://doi.org/10.1186/s12991-020-00309-z

Other articles of this Issue 1/2020

Annals of General Psychiatry 1/2020 Go to the issue

Review

How to improve adherence to antidepressant treatments in patients with major depression: a psychoeducational consensus checklist

Primary research

Psychometric investigation of the French version of the Aberrant Salience Inventory (ASI): differentiating patients with psychosis, patients with other psychiatric diagnoses and non-clinical participants

Primary research

Untreated depressive symptoms significantly worsen quality of life in old age and may lead to the misdiagnosis of dementia: a cross-sectional study

Primary research

Attenuated relationship between salivary oxytocin levels and attention to social information in adolescents and adults with autism spectrum disorder: a comparative study

Review

Prevalence of perinatal depression among Japanese women: a meta-analysis

Primary research

The anxious aspects of insecure attachment styles are associated with depression either in pregnancy or in the postpartum period